Polymorphism in microRNA-binding site in HNF1B influences the susceptibility of type 2 diabetes mellitus: A population based case-control study

BMC Medical Genetics

Volumn 16, Issue 1, 2015, Pages

  Goda, Naoki ^a   Murase, Haruna ^a   Kasezawa, Nobuhiko ^b,c   Goda, Toshinao ^a   Yamakawa Kobayashi, Kimiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA MEDICAL CENTER   (Japan)

^c Department of Data Managements for Health Evaluation and Promotion Shizuoka Medical Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HSA MICRORNA 214 5P; HSA MICRORNA 550A 5P; MICRORNA; UNCLASSIFIED DRUG; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, HUMAN; LUCIFERASE;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC REGULATION; HNF1B GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; JAPAN; MALE;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; JAPAN; LUCIFERASES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84940549308     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/s12881-015-0219-5     Document Type: Article

References (45)

1. Stumvoll MA, Goldstein BA, van Haeften TA. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-46.
2. O'Rahilly SA, Barroso IA, Wareham NA. Genetic factors in type 2 diabetes: the end of the beginning? Science. 2005;307:370-3.
3. Ashcroft FA, Rorsman PA. Diabetes mellitus and the β cell: the last ten years. Cell. 2012;148:1160-71.
4. Ayub QA, Moutsianas LA, Chen YA, Panoutsopoulou KA, Colonna VA, Pagani LA, et al. Revisiting the thrifty gene hypothesis via 65 loci associated with susceptibility to type 2 diabetes. Am J Hum Genet. 2014;94:176-85.
5. Hara KA, Shojima NA, Hosoe JA, Kadowaki TA. Genetic architecture of type 2 diabetes. Biochem Biophys Res Commun. 2014;452:213-20.
6. Mahajan AA, Go MA, Zhang WA, Below JA, Gaulton KA, Ferreira TA, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234-44.
7. Bartel DA. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
8. Erson AA, Petty EA. MicroRNAs in development and disease. Clin Genet. 2008;74:296-306.
9. Ryan BA, Robles AA, Harris CA. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389-402.
10. Bandiera SA, Hatem EA, Lyonnet SA, Henrion-Caude AA. microRNAs in diseases: from candidate to modifier genes. Clin Genet. 2010;77:306-13.
11. Mendell JA, Olson EA. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172-87.
12. Hamar PA. Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther. 2012;22:289-94.
13. Locke JA, da Silva Xavier GA, Dawe HA, Rutter GA, Harries LA. Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion. Diabetologia. 2014;57:122-8.
14. Liu CA, Rennie WA, Carmack CA, Kanoria SA, Cheng JA, Lu JA, et al. Effects of genetic variations on microRNA: target interactions. Nucleic Acids Res. 2014;42:9543-52.
15. WHO Diabetes Programme, About diabetes, http://www.who.int/diabetes/action_online/basics/en/index1.html Accessed 27 Apr 2015.
16. Yamakawa-Kobayashi K, Natsume M, Aoki S, Nakano S, Inamori T, Kasezawa N, et al. The combined effect of the T2DM susceptibility genes is an important risk factor for T2DM in non-obese Japanese: a population based case-control study. BMC Med Genet. 2012;13:11.
17. Villegas R, Williams SM, Gao YT, Long J, Shi J, Cai H, et al. Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes. Ann Hum Genet. 2014;78:23-32.
18. Bodhini D, Radha V, Deepa R, Ghosh S, Majumder PP, Rao MRS, et al. The G1057D polymorphism of IRS-2 gene and its relationship with obesity in conferring susceptibility to type 2 diabetes in Asian Indians. Int J Obese. 2007;31:97-102.
19. Imamura M, Iwata M, Maegawa H, Watada H, Hirose H, Tanaka Y, et al. Genetic variants at CDC123/CAMK1D and SPRY2 are associated with susceptibility to type 2 diabetes in the Japanese population. Diabetologia. 2011;54:3071-7.
20. Liu CA, Zhang FA, Li TA, Lu MA, Wang LA, Yue WA, et al. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012;13:661.
21. MirSNP; A collection of human SNPs in predicted miRNA target sites: Peking University, China. 2012 http://bioinfo.bjmu.edu.cn/mirsnp/search/ Accessed 24 August 2015.
22. Bhattacharya AA, Ziebarth JA, Cui YA. PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res. 2014;42:D86-91.
23. PolymiRTS Database 3.0: University of Tennessee Health Science Center, TN. 2013. http://compbio.uthsc.edu/miRSNP/ Accessed 30 Apr 2015.
24. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254-63.
25. miRNASNP: Huazhong University of Science and Technology, China. 2014. http://bioinfo.life.hust.edu.cn/miRNASNP2/ Accessed 30 Apr 2015.
26. QUANTO Version 1.2: by Jim Gauderman, Ph.D. and John Morrison, M.S. University of Southern California http://biostats.usc.edu/software.html Accessed 27 July 2015.
27. Cereghini SA. Liver-enriched transcription factors and hepatocyte. FASEB J. 1996;10:267-82.
28. Edghill EA, Bingham CA, Ellard SA, Hattersley AA. Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J Med Genet. 2006;43:84-90.
29. Coffinier CA, Thepot DA, Babinet CA, Yaniv MA, Barra JA. Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development. 1999;126:4785-94.
30. Maestro MA, Boj SA, Luco RA, Pierreux CA, Cabedo JA, Servitja JA, et al. Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. Hum Mol Genet. 2003;12:3307-14.
31. Servitja JA, Ferrer JA. Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia. 2004;47:597-613.
32. Horikawa YA, Iwasaki NA, Hara MA, Furuta HA, Hinokio YA, Cockburn BA, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2). Nat Genet. 1997;17:384-5.
33. Fajans SA, Bell GA, Polonsky KA. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971-80.
34. Fajans SA, Bell GA. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878-84.
35. Yamagata K. Regulation of pancreatic beta-cell function by the HNF transcription network: lessons from maturity-onset diabetes of the young (MODY). Endocrine J. 2003;50:491-9.
36. Prokopenko IA, McCarthy MA, Lindgren CA. Type 2 diabetes: new genes, new understanding. Trends Genet. 2008;24:613-21.
37. Billings LA, Florez JA. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59-77.
38. Zhang XA, Qiao HA, Zhao YA, Wang XA, Sun HA, Liu AA, et al. Association of single nucleotide polymorphisms in TCF2 with type 2 diabetes susceptibility in a Han Chinese population. PLoS One. 2012;7, e52938.
39. Kornfeld JA, Baitzel CA, Konner AA, Nicholls HA, Vogt MA, Herrmanns KA, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013;494:111-15.
40. Joglekar MV, Parekh VS, Hardikar AA. New pancreas from old: microregulators of pancreas regeneration. Trends Endocrinol Metabol. 2007;18:393-400.
41. Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, et al. miR-214 targets ATF4 to inhibit bone formation. Nature Med. 2013;19:93-100.
42. Tian Q, Liang L, Ding J, Zha R, Shi H, Wang Q, et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PloS One. 2012;7, e48958.
43. Yoshiuchi I, Yamagata K, Zhu Q, Tamada I, Takahashi Y, Onigata K, et al. Identification of a gain-of-function mutation in the HNF-1beta gene in a Japanese family with MODY. Diabetologia. 2002;45:154-5.
44. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303:1378-81.
45. Kulkarni RN, Kahn CR. Molecular biology. HNFs-linking the liver and pancreatic islets in diabetes. Science. 2004;303:1311-12.